This database contains 370 studies, archived under the term: "treatment outcome"
Click here to filter this large number of results.
Cognitive effects of memantine in postmenopausal women at risk of dementia: a pilot study
Wroolie, T. E.,
Kenna, H. A.,
Williams, K. E.,
Powers, B. N.,
Holcomb, M.,
Lazzeroni, L.,
Rasgon, N. L.
Background: To determine the effects of memantine on cognition in a normal population of postmenopausal women with putative risk factors for Alzheimer’s disease (AD) using a built-in control for the genetic risk factor for AD (apoE-epsilon4 status).; Methods: A prospective, open-label, 6-month pilot medication trial with memantine and follow-up after discontinuance conducted at the Center […]
Effectiveness of donepezil in reducing clinical worsening in patients with mild-to-moderate alzheimer’s disease
Wilkinson, David,
Schindler, Rachel,
Schwam, Elias,
Waldemar, Gunhild,
Jones, Roy W.,
Gauthier, Serge,
Lopez, Oscar L.,
Cummings, Jeffrey,
Xu, Yikang,
Feldman, Howard H.
Background: Therapeutic endpoints based on reduced clinical worsening represent clinically relevant and realistic goals for patients suffering from progressive neurodegenerative disorders such as Alzheimer’s disease (AD).; Methods: Data from 906 patients (388 receiving placebo; 518 receiving donepezil) with mild-to-moderate AD [Mini-Mental State Examination (MMSE) score 10-27] were pooled from 3 randomized, double-blind placebo-controlled studies. Clinical […]
The effect of multisensory stimulation on persons residing in an extended care facility
Background: Non-pharmacological interventions, such as multisensory stimulation environments (MSSE), have demonstrated the ability to reduce inappropriate behavior among individuals with Alzheimer’s disease.; Methods: In this study, we compared the incidences of problematic behavior among individuals with Alzheimer’s disease residing in a long-term care facility who were and were not exposed to an MSSE. Retrospective data […]
Prazosin for the treatment of behavioral symptoms in patients with Alzheimer disease with agitation and aggression
Wang, Lucy Y.,
Shofer, Jane B.,
Rohde, Kirsten,
Hart, Kim L.,
Hoff, David J.,
McFall, Yun H.,
Raskind, Murray A.,
Peskind, Elaine R.
Objectives: Agitation/aggression in Alzheimer disease (AD) is a major cause of patient distress, caregiver burden, and institutionalization. Enhanced behavioral responsiveness to central nervous system norepinephrine (NE) release may contribute to the pathophysiology of agitation/aggression in AD. Prazosin, a nonsedating generic medication used for hypertension and benign prostatic hypertrophy, antagonizes NE effects at brain postsynaptic alpha-1 […]
Video decision support tool for advance care planning in dementia: randomised controlled trial
Volandes, Angelo E.,
Paasche-Orlow, Michael K.,
Barry, Michael J.,
Gillick, Muriel R.,
Minaker, Kenneth L.,
Chang, Yuchiao,
Cook, E. Francis,
Abbo, Elmer D.,
El-Jawahri, Areej,
Mitchell, Susan L.
Objective: To evaluate the effect of a video decision support tool on the preferences for future medical care in older people if they develop advanced dementia, and the stability of those preferences after six weeks.; Design: Randomised controlled trial conducted between 1 September 2007 and 30 May 2008. Setting Four primary care clinics (two geriatric […]
Therapeutic conversation to improve mood in nursing home residents with Alzheimer’s disease
Few studies have tested strategies to address the mental health needs of individuals with Alzheimer’s disease (AD). To test a newly developed, empirically based modified counseling approach, 30 nursing home residents with AD were randomly assigned to a modified counseling (Therapeutic Conversation) treatment group or usual care control group. Mini-Mental State Examination mean scores were […]
Effect of oxcarbazepine in the treatment of agitation and aggression in severe dementia
Sommer, Oskar H.,
Aga, Olav,
Cvancarova, Milada,
Olsen, Inge C.,
Selbaek, Geir,
Engedal, Knut
Background/aims: To evaluate the efficacy of oxcarbazepine (OXC) in the treatment of agitation and aggression in patients with Alzheimer’s disease, vascular dementia or both.; Methods: This is an 8-week, multicenter, randomized, double-blind, placebo-controlled trial carried out independently of the pharmaceutical industry. Changes in the agitation and aggression subscore of the Neuropsychiatric Inventory (NPI) were the […]
Long-term effects of rivastigmine capsules in patients with traumatic brain injury
Silver, Jonathan M.,
Koumaras, Barbara,
Meng, Xiangyi,
Potkin, Steven G.,
Reyes, Patricio F.,
Harvey, Philip D.,
Katz, Douglas I.,
Gunay, Ibrahim,
Arciniegas, David B.
Objective: To investigate the safety, tolerability and efficacy of rivastigmine capsules (3-12 mg/day) in a 26-week, multi-centre, open-label extension of a double-blind study.; Methods: Patients with traumatic brain injury (TBI) and persistent cognitive impairment who had received rivastigmine (3-6 mg/day) or placebo for 12 weeks could enter the extension study and receive rivastigmine (< or […]